Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Marker antibodies in scleroderma and polymyositis: clinical associations.

Literature DB >> 2547546

Marker antibodies in scleroderma and polymyositis: clinical associations.

D J de Rooij¹, L B Van de Putte, W J Habets, W J Van Venrooij.

Abstract

Sera of 34 patients with progressive systemic sclerosis and of 11 patients with polymyositis/dermatomyositis (PM/DM) were analyzed by the immunoblotting technique for the presence of marker antibodies. The presence of anti-centromere, anti-Topoisomerase-I (anti-Topo-I) and anti-Jo-1 antibodies was found to be highly specific for the CREST syndrome, diffuse scleroderma and PM/DM, respectively, but only of limited sensitivity (78, 44 and 45%, respectively). Anti-Topo-I positive diffuse scleroderma patients had a more severe disease (digital pitting scars and renal insufficiency) than anti-Topo-I negative diffuse scleroderma patients. Anti-Jo-1 was associated with interstitial lung disease. Longitudinal studies showed a constant antibody pattern. Our results confirm the clinical usefulness of these marker antibodies.

Entities: Disease Species

Mesh：

Substances：

Year: 1989 PMID： 2547546 DOI： 10.1007/BF02030079

Source DB: PubMed Journal: Clin Rheumatol ISSN： 0770-3198 Impact factor: 2.980

23 in total

1. The use of immunoblotting to detect antibodies to nuclear and cytoplasmic antigens. Clinical and serological associations in rheumatic diseases.

Authors: D J de Rooij; L B van de Putte; W J Habets; A L Verbeek; W J van Venrooij
Journal: Scand J Rheumatol Date: 1988 Impact factor: 3.641

2. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis.

Authors: A Bohan; J B Peter; R L Bowman; C M Pearson
Journal: Medicine (Baltimore) Date: 1977-07 Impact factor: 1.889

Review 3. Clinical and biochemical characteristics of autoantibody systems in polymyositis and dermatomyositis.

Authors: E J Fudman; T J Schnitzer
Journal: Semin Arthritis Rheum Date: 1986-05 Impact factor: 5.532

4. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis.

Authors: V D Steen; D L Powell; T A Medsger
Journal: Arthritis Rheum Date: 1988-02

Review 5. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine.

Authors: E M Tan
Journal: Adv Immunol Date: 1982 Impact factor: 3.543

6. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors:
Journal: Arthritis Rheum Date: 1980-05

7. Association of anti-centromere and anti-Scl 70 antibodies in scleroderma. Report of two cases.

Authors: A Ruffatti; A Calligaro; C Ferri; S Bombardieri; P F Gambari; S Todesco
Journal: J Clin Lab Immunol Date: 1985-04

8. Autoantibody to centromere (kinetochore) in scleroderma sera.

Authors: Y Moroi; C Peebles; M J Fritzler; J Steigerwald; E M Tan
Journal: Proc Natl Acad Sci U S A Date: 1980-03 Impact factor: 11.205

9. The CREST syndrome: a distinct serologic entity with anticentromere antibodies.

Authors: M J Fritzler; T D Kinsella
Journal: Am J Med Date: 1980-10 Impact factor: 4.965

10. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis.

Authors: S Yoshida; M Akizuki; T Mimori; H Yamagata; S Inada; M Homma
Journal: Arthritis Rheum Date: 1983-05

4 in total